Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Grows By 28.2%

Aquestive Therapeutics, Inc. (NASDAQ:AQSTGet Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 2,320,000 shares, an increase of 28.2% from the February 29th total of 1,810,000 shares. Based on an average daily volume of 1,870,000 shares, the short-interest ratio is presently 1.2 days.

Insider Activity

In related news, insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the transaction, the insider now owns 984,476 shares of the company’s stock, valued at approximately $5,906,856. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.39% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently bought and sold shares of AQST. Jane Street Group LLC bought a new stake in Aquestive Therapeutics during the first quarter valued at $27,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at about $28,000. Charles Schwab Investment Management Inc. acquired a new stake in Aquestive Therapeutics during the second quarter worth approximately $31,000. Two Sigma Securities LLC bought a new stake in Aquestive Therapeutics in the second quarter worth approximately $36,000. Finally, Jump Financial LLC acquired a new position in Aquestive Therapeutics in the fourth quarter valued at approximately $60,000. Institutional investors own 32.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Raymond James started coverage on Aquestive Therapeutics in a research note on Thursday. They set an “outperform” rating and a $7.00 price target on the stock. JMP Securities boosted their target price on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Friday, March 15th. Finally, HC Wainwright upped their price target on shares of Aquestive Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Monday, March 18th.

View Our Latest Report on AQST

Aquestive Therapeutics Trading Up 3.9 %

Shares of AQST stock opened at $4.26 on Friday. Aquestive Therapeutics has a 1-year low of $0.90 and a 1-year high of $6.23. The stock has a market cap of $312.26 million, a price-to-earnings ratio of -30.43 and a beta of 2.85. The stock has a 50-day moving average of $3.56 and a 200-day moving average of $2.45.

Aquestive Therapeutics (NASDAQ:AQSTGet Free Report) last released its earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The business had revenue of $13.21 million for the quarter, compared to analyst estimates of $11.79 million. Sell-side analysts forecast that Aquestive Therapeutics will post -0.38 earnings per share for the current year.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Read More

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.